Identifying infections as early as possible is essential for devising the appropriate course of action.
Identifying infections as early as possible is essential for devising the appropriate course of action. Accurate and rapid diagnosis of infectious diseases is of paramount importance. Startups and leading healthcare companies have been developing universal tests and rolling out their tests to hospitals and diagnostic centers. Moreover, investors have been coming onboard to expand the tests at the global stage. Companies have been raising funding to expand their reach and develop products. The development of novel diagnostic tools for infectious diseases will increase in the next few years. According to the report published by Allied Market Research, the global infectious disease diagnostic market is estimated to reach $39.94 billion by 2030. Following are some of the activities taking place across the world.
Development of universal tests will help in identifying infections and determining the next course of action. HaystackAnalytics, one of the startups in the healthcare sector, developed a Universal infectious disease (ID) genomic test for rapid and accurate diagnosis of IDs. The startup claimed that it has become the world’s first company to develop genomic-based infectious disease diagnostics. This test involves utilization of next-generation sequencing (NGS) technology for identifying infections and appropriate treatment options.
The startup plans to roll out the tests by partnering with diagnostic centers and hospitals. The startup highlighted that it has been working with top 15 hospitals in India for deployment of the test for patients in ICU. The test will be carried out to identify and treat sepsis in initial phases. Furthermore, it will be utilized for patients suffering from fever as well. The company will roll out its test to nearly 100 hospitals in the country in the next six months. Moreover, the global expansion will be carried out by raising funding.
Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/2011
While some companies await the funding to come; some of the them had already raised. Day Zero Diagnostics, the Boston-based company, raised the funding of $21 million. The funding round was led by Sands Capital. Other investors were BD, Triventures, Hongkou Capital, Panacea Venture, and Golden Seeds. The company has a diagnostic tool that utilizes machine learning and whole-genome sequencing for determining bacterial pathogens. This helps healthcare professionals in determining the appropriate drugs for treatment of infection. The newly-raised funding will be utilized for completing the product engineering phase along with expansion of its DZD Lab Services. The funding is expected to support the vision of the company to detect bacterial infections as rapidly as possible and devise the course of action for treatment.
Major Highlights of the Market Globally-
- By product, the assays & reagents segment was the highest contributor to the infectious disease diagnostic market in 2020.
- On the basis of disease type, the others segment dominated the market in 2020, and is expected to continue this trend during the forecast period.
- Depending on technology, the others segment was the highest contributor to the market in 2020.
- Region wise, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
The Major Key Players are:
- Abbott Laboratories
- Becton Dickinson and Company
- bioMerieus SA
- Bio-Rad Laboratories
- Danaher Corporation
- F Hoffman-La Roche
- Hologic Inc.
- Luminex Corporation
- Qiagen Inc.
- Thermo Fisher Scientific Inc.